松和[b]二甲基二氧化碳胺衍生物作为粉样β (Aβ42) 聚合调节剂
Yusheng Zhao1, Kartar Singh1, Rahul Chowdary Karuturi1
1School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo, N2L 3G1, Ontario, Canada.
ChemMedChem
|July 31, 2024
概括
新型的佐和[b]衍生物调节粉样β 42 (Aβ42) 聚合. 一些化合物抑制Aβ42聚合并保护神经元,而另一些化合物则加速它,为研究聚合机制提供了工具.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 粉样β 42 (Aβ42) 聚合是阿尔茨海默病的关键病理标志.
- 作为潜在的治疗剂和研究工具,人们正在寻找Aβ42聚合的调节剂.
- 硫和[b]基构架代表了药物发现的有前途的化学框架.
研究的目的:
- 设计和合成新型的N-phenylbenzofuran-2-carboxamide和N-phenylbenzo[b]thiophene-2-carboxamide衍生品. 为了设计和合成新型的N-phenylbenzofuran-2-carboxamide和N-phenylbenzo[b]thiophene-2-carboxamide衍生品. 为了设计和合成新型的N-phenylbenzofuran-2-carboxamide和N-phenylbenzo[b]thiophene-2-carboxamide衍生品.
- 为了评估合成的化合物作为Aβ42聚合的调节剂.
- 研究活性化合物的神经保护作用和潜在机制.
主要方法:
- 新型松和[b]衍生物的化学合成.
- 基于Thioflavin-T光的测定用于监测Aβ42聚合动力学.
- 电子显微镜可视化Aβ42纤维形成.
- 使用HT22细胞进行细胞活力测试以评估神经保护.
- 分子对接研究,以预测结合相互作用.
主要成果:
- 化合物4a,4b,5a和5b含有甲氧化药,以度依赖的方式抑制了Aβ42聚合 (由4b抑制高达54%).
- 化合物4d和5d,带有4-甲基环,显著加快了Aβ42纤维生成 (4d增加了2.7倍).
- 化合物5a和5b在HT22细胞中对Aβ42诱导的细胞毒性表现出显著的神经保护作用.
- 电子显微镜和分子对接研究证实了调制效应,并突出了芳香环方向的作用.
结论:
- 合成的N-phenylbenzofuran和N-phenylbenzo[b]thiophene衍生物有效调节Aβ42聚合.
- 特定的结构特征决定了某种化合物是否抑制或加速Aβ42聚合.
- 这些新型化合物作为研究Aβ42聚合途径和开发潜在的阿尔茨海默病治疗方法的宝贵药理工具.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.7K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.7K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.2K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


